Btnl6 Inhibitors
Btnl6 inhibitors are chemical compounds designed to selectively inhibit the activity of the butyrophilin-like 6 (Btnl6) protein, which belongs to the butyrophilin family. These proteins are a sub-group of the immunoglobulin superfamily, which includes molecules that play diverse roles in regulating cellular processes. Btnl6 is primarily involved in modulating interactions between cells, particularly within the immune system, where it influences cell signaling and activation pathways. Inhibiting Btnl6 can therefore interfere with the protein's ability to engage in these cellular communication processes, altering how certain cells respond to environmental stimuli. Btnl6 inhibitors act by binding to specific domains on the Btnl6 protein, disrupting its ability to interact with other proteins or cells, which in turn can modify cellular behavior in response to various signals.
Btnl6 inhibitors are small molecules, peptides, or biologically-derived agents that are optimized to have high specificity for the Btnl6 protein, minimizing the likelihood of cross-reactivity with other proteins in the butyrophilin family. Their development often involves identifying the structural features of Btnl6 that are critical for its function and designing molecules that can selectively block these features. By targeting Btnl6's interaction sites, these inhibitors can help researchers study the biological roles of Btnl6 in immune regulation and cellular signaling. The design and refinement of Btnl6 inhibitors require detailed knowledge of the protein's structure, function, and interaction networks to ensure effective modulation of its activity within cellular systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
A specific inhibitor of NF-κB signaling. By blocking NF-κB activation, it indirectly influences Btnl6 expression, as NF-κB is involved in the transcriptional regulation of genes related to inflammation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor targeting the MAPK pathway. By suppressing c-Jun N-terminal kinase activity, it indirectly modulates Btnl6 expression, as JNK is implicated in the regulation of key cellular processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor blocking the PI3K-AKT pathway. Indirectly, it affects Btnl6 by modulating the PI3K signaling cascade, which plays a role in cell survival, proliferation, and immune responses. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor blocking the mTOR signaling pathway. It indirectly influences Btnl6 expression by modulating mTOR-dependent cellular processes, impacting immune responses and inflammatory signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAP kinase inhibitor affecting the MAPK pathway. This indirect modulation influences Btnl6 expression, as p38 MAP kinase is a key regulator of inflammatory responses and cellular stress. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
A MEK inhibitor disrupting the MAPK/ERK pathway. By inhibiting MEK1/2, it indirectly influences Btnl6 expression, as the MAPK/ERK pathway is involved in cellular proliferation and immune responses. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
A JAK2 inhibitor targeting the JAK-STAT pathway. Its indirect influence on Btnl6 involves the inhibition of JAK2, affecting downstream STAT signaling and subsequently altering cellular responses. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A phosphoinositide 3-kinase (PI3K) inhibitor disrupting the PI3K-AKT pathway. This indirect inhibition impacts Btnl6 by altering the PI3K-mediated signaling cascades that converge on Btnl6 regulation. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
An AKT kinase inhibitor impacting the PI3K-AKT pathway. Its indirect modulation of Btnl6 involves altering AKT signaling, affecting cellular processes related to immune regulation and inflammatory responses. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
An inhibitor of JAK1 and JAK2. By blocking JAK signaling, it indirectly influences Btnl6 expression, as JAK-STAT pathways play a crucial role in immune responses and inflammatory signaling. | ||||||